Side-by-side · Research reference
5-Amino-1MQvsLiraglutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongDraft8/38 cited
BFDA-ApprovedVerified14/45 cited
5-Amino-1MQ
NNMT inhibitor · Methylation / SAM modulation
Oral · Once daily fasted
Liraglutide
Daily GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once daily
01Mechanism of Action
Parameter
5-Amino-1MQ
Liraglutide
Primary target
Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018
GLP-1 receptor (GLP-1R)SAXENDA (liraglutide) injectio 2014
Pathway
NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018
GLP-1R agonism → ↑glucose-dependent insulin, ↓glucagon, ↓gastric emptying, ↓appetiteSAXENDA (liraglutide) injectio 2014Marso 2016
Downstream effect
Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018
Glycemic improvement, modest body-weight reduction, cardiovascular event reduction in high-risk T2DMarso 2016
Feedback intact?
—
Glucose-dependent insulin release preserves physiological feedback
Origin
Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018
Modified GLP-1(7-37) with Lys26 substitution (Arg34) and C-16 palmitoyl-glutamate acylation for albumin bindingSAXENDA (liraglutide) injectio 2014
Antibody development
—
—
02Dosage Protocols
Parameter
5-Amino-1MQ
Liraglutide
Frequency
Once daily, fasted
Once daily, same time each day
Lower / starter dose
50 mg / day
—
Evidence basis
Animal-strong; no human RCT dataNeelakantan 2018
FDA-approved · Phase 3 RCTs (LEADER, SCALE)Marso 2016SAXENDA (liraglutide) injectio 2014
Duration
8–12 weeks per cycle
Indefinite for chronic indication
Form
Oral capsule
—
Timing
Morning fasted preferred
Any time of day; consistent
Standard dose (weight, Saxenda)
—
3.0 mg / day (after 5-week titration)SAXENDA (liraglutide) injectio 2014
Titration schedule
—
0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks
Mitigates GI side effects.
Reconstitution
—
Pre-filled commercial pen (no reconstitution)
04Side Effects & Safety
Parameter
5-Amino-1MQ
Liraglutide
GI symptoms
Mild nausea (anecdotal)
Nausea, vomiting, diarrhea (very common during titration)SAXENDA (liraglutide) injectio 2014
Methylation disruption
Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)
—
Long-term safety
Unknown — no human trials
—
Cancer risk
Unclear — NNMT also studied in oncology contexts
—
Pregnancy / OB
Avoid
Contraindicated
Drug interactions
Theoretical with niacin / B-vitamin supplements
—
Pancreatitis risk
—
Rare; discontinue if suspected
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / MTC historySAXENDA (liraglutide) injectio 2014
Hypoglycemia
—
Low risk as monotherapy; elevated with sulfonylureas / insulin
Heart rate
—
Modest ↑ resting HR (~2-3 bpm)
Absolute Contraindications
5-Amino-1MQ
- ·Pregnancy / breastfeeding
- ·Active malignancy
Liraglutide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to liraglutide
Relative Contraindications
5-Amino-1MQ
- ·Methylation-sensitive conditions (MTHFR mutation)
- ·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)
Liraglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Severe gastrointestinal disease
05Administration Protocol
Parameter
5-Amino-1MQ
Liraglutide
1. Form
Oral capsule. No injection.
Commercial pre-filled pen, no reconstitution required.
2. Administration
Take with water, fasted preferred.
SQ — abdomen, thigh, or upper arm. Rotate sites.
3. Timing
Morning fasted.
Once daily, same time each day. Take with or without food.
4. Storage
Room temp ≤25 °C, dry place.
Refrigerate 2–8 °C unopened; room temp ≤30 °C up to 30 days after first use.
5. Caveat
Monitor B-vitamin status with chronic use.
Pen-supplied 32G needle.